Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

• Published in: Annals of hematology Vol. 89; no. 11; pp. 1133 - 1140
• Main Authors: Buda, Gabriele, Ricci, Deborah, Huang, C. Chris, Favis, Reyna, Cohen, Nadine, Zhuang, Sen H, Harousseau, Jean-Luc, Sonneveld, Pieter, Bladé, Joan, Orlowski, Robert Z
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Berlin/Heidelberg : Springer-Verlag 01.11.2010; Springer-Verlag; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; analogs & derivatives; Antineoplastic Agents; Antineoplastic Agents - therapeutic use; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B - genetics; ATP Binding Cassette Transporter, Subfamily B - metabolism; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics; ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism; ATP-Binding Cassette Sub-Family B Member 4; Boronic Acids; Boronic Acids - therapeutic use; Bortezomib; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Doxorubicin; Doxorubicin - analogs & derivatives; Doxorubicin - therapeutic use; drug therapy; genetics; Hematology; Humans; Kaplan-Meier Estimate; MDR1; Medicine; Medicine & Public Health; metabolism; Middle Aged; MRP1; Multiple Myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - genetics; Multiple Myeloma - metabolism; myeloma; Oncology; Original; Original Article; Pegylated liposomal doxorubicin; Polyethylene Glycols; Polyethylene Glycols - therapeutic use; Polymorphism, Single Nucleotide; Pyrazines; Pyrazines - therapeutic use; Recurrence; Retrospective Studies; SNP; therapeutic use; Time Factors; MDR1; MRP1; Bortezomib; SNP; Pegylated liposomal doxorubicin; Multiple myeloma

Single nucleotide polymorphisms (SNPs) in the multiple drug resistance protein 1 (MRP1) and P-glycoprotein 1 (MDR1) genes modulate their ability to mediate drug resistance. We therefore sought to retrospectively evaluate their influence on outcomes in relapsed and/or refractory myeloma patients trea...